Positive I-123-MIBG-Scintigraphy in Osteosarcoma

Summary

I-123-MIBG scintigraphy has become a standard imaging technique in the detection of neuroendocrine or neurocrest derived tumors, especially neuroblastoma and pheochromocytoma. We report on a positive I-123-MIBG uptake in a pediatric osteosarcoma patient and demonstrate, that unusual results still occur with this established imaging method.

Zusammenfassung

Die sI-123-MIBG-Szintigraphie ist eine Standarduntersuchung in der bildgebenden Diagnostik von neuroendokrinen Tumoren bzw. von Tumoren, die sich von Neuralleistengewebe ableiten lassen (insbesondere Neuroblastome und Phäochromozytome). Wir berichten von einer positiven I-123-MIBG-Szintigraphie bei einer jugendlichen Patientin mit Osteosarkom und zeigen, daß noch immer mit ungewöhnlichen Ergebnissen bei dieser etablierten Standarduntersuchung gerechnet werden muß.

Keywords

I-123-MIBG scintigraphy - osteosarcoma - pediatric

Schlüsselwörter

I-123-MIBG Szintigraphie - Osteosarkom - pädiatrisch

• References

• 1 Bair HJ, Behr T, von der Hardt K. et al. Unusual MIBG uptake patterns in children. 2nd European Symposium on pediatric nuclear medicine Domènech-Tormé FM, Hahn K, Rocca I. (eds) 1995
• 2 Bomanji J, Hungerford JL, Kingston JE. et al. 123-1 metaiodobenzylguanidine (MIBG) scintigraphy of retinoblastoma: preliminary experience. Br J Ophthalm 1989; 73: 146-50.
• 3 Bonnin F, Lumbroso J, Tenenbaum F. et al. Refining interpretation of MIBG Scans in children. J Nucl Med 1994; 35: 803-10.
• 4 Bouvier JF, Philip T, Chauvot P. et al. Pitfalls and solutions in neuroblastome diagnosis using radioiodine MIBG. Prog Clin Biol Res 1988; 271: 707-20.
• 5 Buck J, Bruchelt G, Girgert R. et al. Specific uptake of m(125-I)iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH. Cancer Res 1985; 45: 6366-70.
• 6 Feggi L, Degli Uberti E, Pansini GC. et al. Pitfalls in scintigraphic detection of neuroendocrine tumours. Eur J Nucl Med 1992; 19: 214-8.
• 7 Geatti O, Shapiro B, Barillari B. Scintigraphic depiction of an insulinoma by I-131 metaiodobenzylguanidine. Clin Nucl Med 1989; 14: 903-5.
• 8 Hayward RS, Bowering CK, Warshawski RS. I-131 metaiodobenzylguanidine uptake in a parathyroid adenoma. Clin Nucl Med 1988; 13: 632-4.
• 9 Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumors. Eur J Nucl Med 1994; 21: 561-81.
• 10 Home T, Glaser B, Krausz Y. et al. Unusual causes of I-131 metaiodobenzylguanidine uptake in non-neural crest tissue. Clin Nucl Med 1991; 16: 239-42.
• 11 Jaques S, Tobes MC, Sisson JC. et al. Comparison of the sodium dependency of uptake of meta-iodobenzylguanidine and norepinephrine into cultured bovine adrenomedul-lary cells. Mol Pharmacol 1984; 26: 539-46.
• 12 Jaques S, Tobes MC, Sisson JC. Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one. Cancer Res 1987; 47: 3920-8.
• 13 von Moll L, McEwan AJ, Shapiro B. Iodine-131 MIBG Scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma. J Nucl Med 1987; 28: 979-88.
• 14 Muino Miguez A, Robles Perez R, Lopez Gomez JM. et al. Falso positivo con MIBG en la localización del feocromocitoma. Medicina Clínica 1986; 86: 437.
• 15 Parisi MT, Sandler ED, Hattner RS. The biodistribution of metaiodobenzylguanidine. Sem Nucl Med 1992; 22: 46-8.
• 16 Saint-Andre JP, Chapeau MC, Pein F. Nephroblastome avec differentiation neuronale symptomatique. Ann Path 1988; 8: 144-8.
• 17 Shapiro B, Copp JE, Sisson JC. Iodine-131 Metaiodobenzylguanidine for the locating of suspected pheochromocytoma: Experience in 400 cases. J Nucl Med 1985; 26: 576-85.
• 18 Smets LA, Loesberg C, Janssen M. et al. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res 1989; 49: 2941-4.
• 19 Stewart RE, Grossmann DM, Shulkin BL. et al. Iodine-131 metaiodobenzylguanidine uptake in infantile myofibromatosis. Clin Nucl Med 1989; 14: 344-6.
• 20 Treuner J. Aspekte der Anwendung von 131 J-Metajodbenzylguanidin aus der Sicht der paediatrischen Onkologie. Nuklearmedizin 1985; 24: 26-8.